Finally, while we demonstrated that AnxA5-antigenic peptide fusion proteins have similar therapeutic antitumor effects against TC-1 and CT26 tumor models, further evaluations in additional tumor models is warranted to assess any potential treatment variations. Here, ANXA5 is linked to neoplasm.